Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC

Journal of Infection

Volumn 67, Issue 4, 2013, Pages 348-350

  Du, Lanying ^a   Ma, Cuiqing ^a   Jiang, Shibo ^a,b  

^a NEW YORK BLOOD CENTER   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS SPIKE PROTEIN;

ANIMAL EXPERIMENT; BIOINFORMATICS; CONTROLLED STUDY; CORONAVIRUS; CROSS REACTION; LETTER; MOUSE; NONHUMAN; PROTEIN DOMAIN; RECEPTOR BINDING DOMAIN; SARS CORONAVIRUS; VIRUS NEUTRALIZATION;

EID: 84882865941     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.05.002     Document Type: Letter

References (12)

1. Chan K.H., Fuk-Woo C.J., Tse H., Chen H., Choi-Yi L.C., Cai J.P., et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect 2013 Apr 10, [Epub ahead of print]. 10.1016/j.jinf.2013.03.015.
2. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426:450-454.
3. Wong S.K., Li W., Moore M.J., Choe H., Farzan M.A. 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 2004, 279:3197-3201.
4. Raj V.S., Mou H., Smits S.L., Dekkers D.H., Muller M.A., Dijkman R., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495:251-254.
5. Jiang S., Lu L., Du L., Debnath A.K. A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J Infect 2013, 66:464-466.
6. He Y., Lu H., Siddiqui P., Zhou Y., Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005, 174:4908-4915.
7. Du L., Zhao G., Chan C.C., Sun S., Chen M., Liu Z., et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 2009, 393:144-150.
8. Du L., He Y., Zhou Y., Liu S., Zheng B.J., Jiang S. The spike protein of SARS-CoV - a target for vaccine and therapeutic development. Nat Rev Microbiol 2009, 7:226-236.
9. Zaki A.M., van B.S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-1820.
10. Chan J.F., Li K.S., To K.K., Cheng V.C., Chen H., Yuen K.Y. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic?. J Infect 2012, 65:477-489.
11. He Y., Li J., Du L., Yan X., Hu G., Zhou Y., et al. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine 2006, 24:5498-5508.
12. Elshabrawy H.A., Coughlin M.M., Baker S.C., Prabhakar B.S. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS One 2012, 7:e50366.